ATE257844T1 - Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol - Google Patents
Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykolInfo
- Publication number
- ATE257844T1 ATE257844T1 AT96905057T AT96905057T ATE257844T1 AT E257844 T1 ATE257844 T1 AT E257844T1 AT 96905057 T AT96905057 T AT 96905057T AT 96905057 T AT96905057 T AT 96905057T AT E257844 T1 ATE257844 T1 AT E257844T1
- Authority
- AT
- Austria
- Prior art keywords
- hgf
- polyethylene glycol
- growth factor
- altered
- human growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
- Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
- Control Of Transmission Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7966995 | 1995-03-10 | ||
| PCT/JP1996/000599 WO1996028475A1 (en) | 1995-03-10 | 1996-03-07 | Peg-modified hgf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257844T1 true ATE257844T1 (de) | 2004-01-15 |
Family
ID=13696591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96905057T ATE257844T1 (de) | 1995-03-10 | 1996-03-07 | Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5977310A (de) |
| EP (1) | EP0816381B1 (de) |
| JP (1) | JP4067058B2 (de) |
| AT (1) | ATE257844T1 (de) |
| DE (1) | DE69631329T2 (de) |
| WO (1) | WO1996028475A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284246B1 (en) | 1997-07-30 | 2001-09-04 | The Procter & Gamble Co. | Modified polypeptides with high activity and reduced allergenicity |
| BR9909130A (pt) | 1998-03-26 | 2000-12-19 | Procter & Gamble | Variantes de protease de serina tendo substituições de amino-ácido |
| US6495136B1 (en) | 1998-03-26 | 2002-12-17 | The Procter & Gamble Company | Proteases having modified amino acid sequences conjugated to addition moieties |
| US6908757B1 (en) | 1998-03-26 | 2005-06-21 | The Procter & Gamble Company | Serine protease variants having amino acid deletions and substitutions |
| WO2000062785A1 (en) * | 1999-04-15 | 2000-10-26 | Takara Shuzo Co., Ltd. | Remedies |
| KR20020021397A (ko) | 1999-07-22 | 2002-03-20 | 데이비드 엠 모이어 | 규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체 |
| BR0012694A (pt) | 1999-07-22 | 2002-04-09 | Procter & Gamble | Conjugado de protease, composição de limpeza e composição de tratamento pessoal |
| US6946128B1 (en) | 1999-07-22 | 2005-09-20 | The Procter & Gamble Company | Protease conjugates having sterically protected epitope regions |
| CA2376045A1 (en) | 1999-07-22 | 2001-02-01 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
| ATE375168T1 (de) * | 2000-08-28 | 2007-10-15 | Damavand Wound Ab | Die synergistischen wirkungen von hgf und antibakterieller behandlung |
| ATE421535T1 (de) | 2000-10-16 | 2009-02-15 | Chugai Pharmaceutical Co Ltd | Peg-modifiziertes erythropoietin |
| EP1234583A1 (de) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-Konjugate des HGF-NK4 |
| WO2004019991A2 (en) * | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| JP2004196770A (ja) * | 2002-10-24 | 2004-07-15 | Effector Cell Institute Inc | 樹状細胞前駆体の血中レベル上昇剤 |
| NZ541365A (en) | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| WO2005047337A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| DE602005003929T2 (de) * | 2004-03-03 | 2008-12-04 | F. Hoffmann-La Roche Ag | Verfahren zur aufreinigung eines n-terminalen fragments des hepatozytenwachstumsfaktors |
| AU2005326226B2 (en) | 2005-01-31 | 2010-11-11 | Eci, Inc. | Immunopotentiating agent |
| JP4356648B2 (ja) | 2005-05-10 | 2009-11-04 | トヨタ自動車株式会社 | 変速時トルクダウン制御を行うエンジン制御装置 |
| US20080083154A1 (en) * | 2006-10-05 | 2008-04-10 | Timothy M Gregory | Bait retention fish hook |
| EP2175878A4 (de) * | 2007-07-11 | 2014-12-03 | Belrose Pharma Inc | Polymer-arzneiabgabesystem mit einem mehrfach substituierten aromatischen teil |
| CA2693645A1 (en) * | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery systems containing an aromatic allylic acid |
| JP5641454B2 (ja) * | 2010-11-26 | 2014-12-17 | 独立行政法人物質・材料研究機構 | バイオハイブリッド材料、その製造方法及びステント |
| EA020425B1 (ru) * | 2011-12-21 | 2014-11-28 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Ковалентный конъюгат полиэтиленгликоля с гранулоцитарным колониестимулирующим фактором человека |
| US20220220176A1 (en) * | 2019-01-28 | 2022-07-14 | Toray Industries, Inc. | Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof |
| WO2020158690A1 (ja) | 2019-01-28 | 2020-08-06 | 東レ株式会社 | 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH084504B2 (ja) * | 1985-04-26 | 1996-01-24 | 味の素株式会社 | 安定化ス−パ−オキサイドジスムタ−ゼ |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| JP2931622B2 (ja) * | 1989-05-27 | 1999-08-09 | 住友製薬株式会社 | ポリエチレングリコール誘導体を得る製造方法 |
| JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US6565841B1 (en) * | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5316921A (en) * | 1992-05-18 | 1994-05-31 | Genentech, Inc. | Single-chain hepatocyte growth factor variants |
| DE69310525T2 (de) * | 1992-09-16 | 1997-10-02 | Genentech Inc | Schutz gegen leberschäden mit hgf |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| WO1994023740A1 (en) * | 1993-04-22 | 1994-10-27 | Celtrix Pharmaceuticals, Inc. | Conjugates of growth factor and bone resorption inhibitor |
-
1996
- 1996-03-07 AT AT96905057T patent/ATE257844T1/de not_active IP Right Cessation
- 1996-03-07 EP EP96905057A patent/EP0816381B1/de not_active Expired - Lifetime
- 1996-03-07 DE DE1996631329 patent/DE69631329T2/de not_active Expired - Lifetime
- 1996-03-07 US US08/913,236 patent/US5977310A/en not_active Expired - Lifetime
- 1996-03-07 WO PCT/JP1996/000599 patent/WO1996028475A1/ja not_active Ceased
- 1996-03-07 JP JP52746396A patent/JP4067058B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0816381B1 (de) | 2004-01-14 |
| WO1996028475A1 (en) | 1996-09-19 |
| DE69631329D1 (de) | 2004-02-19 |
| US5977310A (en) | 1999-11-02 |
| EP0816381A4 (de) | 1999-05-06 |
| EP0816381A1 (de) | 1998-01-07 |
| JP4067058B2 (ja) | 2008-03-26 |
| DE69631329T2 (de) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69631329D1 (de) | Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol | |
| UA27911C2 (uk) | Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну | |
| DE59109222D1 (de) | Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen | |
| DK0691130T3 (da) | Anvendelse af rapamycin til fremstilling af et lægemiddel til forebyggelse og behandling af hyperproliferative vaskulære sygdomme, eventuelt i kombination med mycophenolsyre | |
| EE9400356A (et) | Polüetüleenglükool proteiin konjugaadid, ühendid, nende kasutamine, meetod konjugaatide valmistamiseks ja ravimvormid | |
| BE2013C033I2 (de) | ||
| ATE114113T1 (de) | Verwendung von droloxifen bei der behandlung von knochenerkrankungen. | |
| ATE241334T1 (de) | Mittel zur förderung des haarwachstums | |
| DE69101080D1 (de) | Diätfaser, Verfahren und physiologische aktive Zusammensetzung, die diese als aktives Ingredient enhält. | |
| DE69814394D1 (de) | Verwendung von levobupivacain | |
| DE59204364D1 (de) | Zahnärztlicher Patientenstuhl. | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| DK0983072T4 (da) | Fruktanholdige sammensætninger til forebyggelse og behandling af coloncancer | |
| IT9041529A1 (it) | Dispositivo per la correzione chirurgica dell'ametropia. | |
| ATE345809T1 (de) | Arzneimittelzusammensetzung enthaltend tcf-ii | |
| CY1106882T1 (el) | Τροποποιηση βητακυτταρουλινης | |
| DE59101818D1 (de) | Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung. | |
| FI930269A7 (fi) | Koostumus, joka aikaansaa bioaktiivisten aineiden parannetun poistuman verivirrasta | |
| PT941046E (pt) | Composicao para a deformacao permanente das fibras queratinias, obtencao e colocacao em pratica | |
| FR2680953B1 (fr) | Semelle deodorante, antibacteries, hydrothermique jetable. | |
| ES1023298Y (es) | Armazon de coronas funerarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |